Sol-Gel Technologies Ltd. (IL0011417206)
XSTU 
Summary
SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know
Sol-Gel's fourth-quarter 2024 earnings are likely to have gained from higher licensing revenues from its partners.
Is SolGel Technologies (SLGL) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know
SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sol-Gel Technologies Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Moshe Arkin CEO | XSTU Exchange | IL0011417206 ISIN |
| IL Country | 34 Employees | - Last Dividend | - Last Split | 23 Jan 2018 IPO Date |
Overview
Sol-Gel Technologies Ltd. is a specialty pharmaceutical company in the clinical stage, based in Israel, that specializes in the development and commercialization of innovative topical dermatological drugs. Leveraging its proprietary microencapsulation delivery system, the company is devoted to addressing unmet medical needs by creating new therapies with potential benefits over existing treatments. Formed in 1997, Sol-Gel has established a significant footprint in dermatology, driven by its robust pipeline of product candidates and a strategic collaboration with Perrigo. The company's primary focus is on diseases such as acne vulgaris, papulopustular rosacea, palmoplantar keratoderma, and rare skin conditions including Gorlin Syndrome.
Products and Services
- Twyneo
- Epsolay
- SGT-210
- SGT-610
- Erlotinib and Tapinarof
- Generic Topical Dermatological Drug Products
A groundbreaking, once-daily, non-antibiotic topical cream designed for the effective treatment of acne vulgaris. Twyneo has successfully completed Phase III clinical trials, demonstrating its potential as a leading acne treatment.
A novel, once-daily topical cream developed for treating papulopustular rosacea, Epsolay has completed Phase III clinical trials. Its microencapsulation delivery system uniquely positions it as a potentially transformative therapeutic option.
Currently in Phase I clinical trials, SGT-210 represents Sol-Gel's efforts to treat palmoplantar keratoderma, emphasizing the company's dedication to addressing rare and challenging dermatological conditions.
Targeting the rare disease Gorlin Syndrome, SGT-610 has completed Phase II clinical trials. This highlights Sol-Gel’s commitment to developing solutions for lesser-known, yet impactful, skin diseases.
These promising compounds are in development to treat other rare skin indications, showcasing Sol-Gel's broad approach to leveraging its microencapsulation technology for various therapeutic applications.
Alongside its innovative product pipeline, Sol-Gel is also involved in the development of generic topical dermatological drugs, aiming to offer effective and accessible treatment options within the broader market.
Contact Information
